You just read:

The Lancet Oncology publishes head-to-head study comparing first and second generation targeted therapies in treatment of EGFR-mutation positive non-small cell lung cancer

News provided by

Boehringer Ingelheim (Canada) Ltd.

May 09, 2016, 08:00 ET